Tag Archive for: biotechnology

STORM Therapeutics’ First-in-Class tRNA methyltransferase inhibitor of METTL1 to be Presented at the 65th Annual ASH Conference

/in

Data demonstrates METTL1 inhibition in vitro at low nanomolar concentrations while displaying high selectivity over other RNA and protein methyltransferases Data provides the first proof-of-concept that pharmacological inhibition of a tRNA methyltransferase affects tumour growth in vitro and in animal models 8 December 2023, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the clinical stage biotechnology company discovering and […]

Read more

Destiny Pharma plc – Business Update

/in

Continued progress on XF-73 partnering discussions Susan Koppy appointed to drive business development activities $2bn XF-73 Nasal market opportunity Brighton, United Kingdom – 29th June 2023: Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development and commercialisation of novel medicines that can prevent life-threatening infections, today provides an update on the […]

Read more

AMSilk to join panel at SynBioBeta Global Synthetic Biology Conference

/in

Munich, Germany, 17 May, 2023: AMSilk GmbH (“AMSilk”), the world’s first industrial supplier of bio-fabricated silk protein materials, today announces it will be attending the SynBioBeta Global Synthetic Biology Conference in California from 23-25 May 2023. AMSilk will be introducing its outstanding technology, based on silk proteins. Ulrich Scherbel, Chief Executive Officer of AMSilk will […]

Read more

BII appointed by the Danish government to run international deep tech start-up accelerator

/in

BioInnovation Institute (BII), an international non-profit foundation incubating and accelerating world-class life science research, announces the launch of a new deep tech accelerator start-up program, the Deep Tech Lab – Quantum, to propel emergent and disruptive quantum science and biotechnology solutions toward the marketplace. Deep tech and quantum science have received significant attention from governmental organizations, […]

Read more

Engimmune Therapeutics appoints Dr. Lars Nieba as Chief Executive Officer

/in

Basel, Switzerland, April 19, 2023. Engimmune Therapeutics AG (“Engimmune”), a Swiss biotech company developing novel T-cell receptor (TCR)-based therapeutics, today announces the appointment of Dr. Lars Nieba as Chief Executive Officer. Dr. Søren Mouritsen, co-founder and previous CEO, steps down in a planned transition. Dr. Lars Nieba brings more than 25 years of experience in […]

Read more